{
    "organizations": [],
    "uuid": "9c898e0b714fc737df4d113c1656d2416996014a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-genmab-gets-usd-50-mln-from-novart/brief-genmab-gets-usd-50-mln-from-novartis-for-lost-potential-milestones-and-royalties-idUSASM000IBS",
    "ord_in_thread": 0,
    "title": "BRIEF-Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 22 (Reuters) - GENMAB:\n* ANNOUNCES NOVARTIS’ INTENTION TO TRANSITION ARZERRA® (OFATUMUMAB) FROM COMMERCIAL AVAILABILITY TO LIMITED AVAILABILITY VIA COMPASSIONATE USE PROGRAMS FOR THE TREATMENT OF CLL IN NON-US MARKETS\n* ‍RECEIVES USD 50 MILLION FROM NOVARTIS AS PAYMENT FOR LOST POTENTIAL MILESTONES AND ROYALTIES​\n* ‍AMOUNT WILL BE INCLUDED IN GENMAB‘S 2018 GUIDANCE​\n* ‍ROYALTIES WILL CONTINUE TO BE EARNED ON NET SALES OF ARZERRA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-22T15:15:00.000+02:00",
    "crawled": "2018-01-23T17:56:19.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "genmab",
        "announces",
        "novartis",
        "intention",
        "transition",
        "ofatumumab",
        "commercial",
        "availability",
        "limited",
        "availability",
        "via",
        "compassionate",
        "use",
        "program",
        "treatment",
        "cll",
        "market",
        "usd",
        "million",
        "novartis",
        "payment",
        "lost",
        "potential",
        "milestone",
        "included",
        "genmab",
        "continue",
        "earned",
        "net",
        "sale",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}